Table 1.
Baseline Characteristics of Lipodystrophy Patients Versus Overweight/Obese Controls
| Lipodystrophy (n = 60) | Overweight/obese (n = 54) | P Value | ||
|---|---|---|---|---|
| Gender, n, % | Females | 54 (90%) | 48 (89%) | 1.0 |
| Males | 6 (10%) | 6 (11%) | ||
| Age, y, mean ± SD | 35.1 ± 13.7 | 37.1 ± 13.6 | .45 | |
| Ethnicity/race, n, % | Caucasian | 40 (67%) | 38 (70%) | .41 |
| Hispanic | 9 (15%) | 10 (19%) | ||
| African-American | 4 (6.6%) | 4 (7.4%) | ||
| Asian | 3 (5%) | 2 (3.7%) | ||
| Other | 4 (6.7%) | 0 | ||
| BMI, kg/m2, mean ± SD | 24.5 ± 4.1 | 34.9 ± 10.1 | <.001 | |
| Plasma leptin, ng/mL | 3.03 (1.22, 7.02) | 35.31 (18.34, 65.24) | <.001 | |
| TGs, mg/dL, geometric mean (25th, 75th percentiles) | 485.4 (252.3, 940.0) | 133.9 (106.8, 193.3) | <.001 | |
| HbA1c, %, mean ± SD | 8.2 ± 2.1 | 5.6 ± 0.7 | <.001 | |
| Fasting glucose, mg/dL | 175 ± 79 | 97 ± 20 | <.001 | |
| Fasting insulin, μU/mL | 35.9 (14.0, 66.2) | 10.4 (6.6, 23.2) | <.001 | |
| Medications, n, % | Statin | 21 (35%) | 8 (14.8%) | .017 |
| Fibrate | 32 (53.3%) | 0 (0%) | <.001 | |
| Fish oil | 19 (31.7%) | 3 (5.5%) | <.001 | |
| Metformin | 36 (60%) | 0 (0%) | <.001 | |
| TZD | 14 (23.3%) | 0 (0%) | <.001 | |
| Insulin | 37 (61.7%) | 0 (0%) | <.001 |